341 related articles for article (PubMed ID: 17214848)
1. Protein expression of melanocyte growth factors (bFGF, SCF) and their receptors (FGFR-1, c-kit) in nevi and melanoma.
Giehl KA; Nägele U; Volkenandt M; Berking C
J Cutan Pathol; 2007 Jan; 34(1):7-14. PubMed ID: 17214848
[TBL] [Abstract][Full Text] [Related]
2. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.
Montone KT; van Belle P; Elenitsas R; Elder DE
Mod Pathol; 1997 Sep; 10(9):939-44. PubMed ID: 9310959
[TBL] [Abstract][Full Text] [Related]
3. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
4. Molecular analysis of melanoma precursor lesions.
Wang Y; Rao U; Mascari R; Richards TJ; Panson AJ; Edington HD; Shipe-Spotloe JM; Donnelly SS; Kirkwood JM; Becker D
Cell Growth Differ; 1996 Dec; 7(12):1733-40. PubMed ID: 8959342
[TBL] [Abstract][Full Text] [Related]
5. Expression of c-kit (CD117) in Spitz nevus and malignant melanoma.
Isabel Zhu Y; Fitzpatrick JE
J Cutan Pathol; 2006 Jan; 33(1):33-7. PubMed ID: 16441409
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
[TBL] [Abstract][Full Text] [Related]
7. Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential.
Huang S; Luca M; Gutman M; McConkey DJ; Langley KE; Lyman SD; Bar-Eli M
Oncogene; 1996 Dec; 13(11):2339-47. PubMed ID: 8957075
[TBL] [Abstract][Full Text] [Related]
8. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.
Nazarian RM; Prieto VG; Elder DE; Duncan LM
J Cutan Pathol; 2010 Apr; 37 Suppl 1():41-7. PubMed ID: 20482674
[TBL] [Abstract][Full Text] [Related]
9. Co-expression of KIT receptor and its ligand stem cell factor in Merkel cell carcinoma.
Krasagakis K; Kruger-Krasagakis S; Eberle J; Tsatsakis A; Tosca AD; Stathopoulos EN
Dermatology; 2009; 218(1):37-43. PubMed ID: 19001805
[TBL] [Abstract][Full Text] [Related]
10. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma.
Massi D; Naldini A; Ardinghi C; Carraro F; Franchi A; Paglierani M; Tarantini F; Ketabchi S; Cirino G; Hollenberg MD; Geppetti P; Santucci M
Hum Pathol; 2005 Jun; 36(6):676-85. PubMed ID: 16021575
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma.
Tron VA; Krajewski S; Klein-Parker H; Li G; Ho VC; Reed JC
Am J Pathol; 1995 Mar; 146(3):643-50. PubMed ID: 7534042
[TBL] [Abstract][Full Text] [Related]
12. Stem cell factor and c-kit are expressed by and may affect vascular SMCs through an autocrine pathway.
Hollenbeck ST; Sakakibara K; Faries PL; Workhu B; Liu B; Kent KC
J Surg Res; 2004 Aug; 120(2):288-94. PubMed ID: 15234225
[TBL] [Abstract][Full Text] [Related]
13. S100A6 protein expression is different in Spitz nevi and melanomas.
Ribé A; McNutt NS
Mod Pathol; 2003 May; 16(5):505-11. PubMed ID: 12748257
[TBL] [Abstract][Full Text] [Related]
14. The dermal stem cell factor and c-kit are overexpressed in melasma.
Kang HY; Hwang JS; Lee JY; Ahn JH; Kim JY; Lee ES; Kang WH
Br J Dermatol; 2006 Jun; 154(6):1094-9. PubMed ID: 16704639
[TBL] [Abstract][Full Text] [Related]
15. Expression of cell cycle and apoptosis regulatory proteins and telomerase in melanocitic lesions.
Batinac T; Hadzisejdić I; Brumini G; Ruzić A; Vojniković B; Zamolo G
Coll Antropol; 2007 Jan; 31 Suppl 1():17-22. PubMed ID: 17469743
[TBL] [Abstract][Full Text] [Related]
16. Expression of SCF splice variants in human melanocytes and melanoma cell lines: potential prognostic implications.
Welker P; Schadendorf D; Artuc M; Grabbe J; Henz BM
Br J Cancer; 2000 Apr; 82(8):1453-8. PubMed ID: 10780526
[TBL] [Abstract][Full Text] [Related]
17. Expression of AP-2alpha, c-kit, and cleaved caspase-6 and -3 in naevi and malignant melanomas of the skin. A possible role for caspases in melanoma progression?
Woenckhaus C; Giebel J; Failing K; Fenic I; Dittberner T; Poetsch M
J Pathol; 2003 Oct; 201(2):278-87. PubMed ID: 14517845
[TBL] [Abstract][Full Text] [Related]
18. Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression.
Einspahr JG; Thomas TL; Saboda K; Nickolof BJ; Warneke J; Curiel-Lewandrowski C; Ranger-Moore J; Duckett L; Bangert J; Fruehauf JP; Alberts DS
Cancer; 2007 Dec; 110(11):2519-27. PubMed ID: 17932890
[TBL] [Abstract][Full Text] [Related]
19. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of vascular endothelial growth factor (VEGF) and C-KIT in cutaneous melanocytic lesions.
Stefanou D; Batistatou A; Zioga A; Arkoumani E; Papachristou DJ; Agnantis NJ
Int J Surg Pathol; 2004 Apr; 12(2):133-8. PubMed ID: 15173918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
